Forecast

Buy	3
Hold	3
Sell	0

News Go to news feed

Evotec reaches Pentagon milestone with Phase‑I clinical study, stock remains weak

Just‑Evotec Biologics launches a Phase‑I study for the orthopox antibody cocktail JST‑018 under a U.S. Department of Defense program; together with a previous contract the potential order volume is up to USD 123.9 million. The project confirms the functionality of Evotec’s continuous‑manufacturing platform through production of clinical material and strengthens the high‑margin biologics division. Chart‑wise, Evotec’s share remains in an intact downtrend and is trading near its 52‑week low, so investors will still need patience and risk tolerance until operational successes are reflected in the group’s financials. » More on finanzen.net
Evotec cooperates with Plectonic Biotech on T-cell engagers, shares fall to multi-year low

Evotec has started a research collaboration with Plectonic Biotech to investigate a new immunotherapy approach and the combination of the BiTco platform with LOGIBODY technology for the treatment of solid tumors. Financial details of the collaboration were not disclosed. Despite the news, Evotec's share briefly fell to a multi-year low of €3.13; there remains a lack of news to support a sustained trend reversal and confidence in the capital markets. » More on deraktionaer.de
Evotec cuts guidance after weak half-year and strengthens restructuring with convertible bond

Evotec reports a 19.2% decline in revenue for H1/2026 to just over €300 million and an adjusted negative EBITDA of €42.7 million. Management attributes the weakness to delayed revenue recognition and lowers the full-year forecast, but expects a pickup in the fourth quarter from increased activity in discovery and preclinical development. To finance » More on finanzen.net

Financials

In the last quarter, Evotec had revenue of €143.48m and net profit of -€46.65m

(EUR)	June 2026	YoY
Revenue	143.48m	16.21%
Gross profit	-1.58m	118.38%
Net profit	-46.65m	7.29%
EBITDA	-26.69m	28.69%

Fundamentals

Metric	Value
Market capitalization	€562.21m
Number of shares	177.19m
52-week high/low	€7.29 - €3.14
Dividends	No
Beta	1.08
P/E ratio	-2.83
PEG ratio	0.03
P/B ratio	0.84
P/S ratio	0.78

Company profile

Evotec SE ist als Wirkstoffforschungs- und -entwicklungspartner für die Pharma- und Biotechnologiebranche weltweit tätig. Das Unternehmen entwickelt pharmazeutische Produkte in verschiedenen therapeutischen Bereichen wie Diabetes und Diabetes-Komplikationen, Fibrose, Infektionskrankheiten, ZNS-Krankheiten, Onkologie, Schmerz und Entzündung, Immunologie, seltene Krankheiten, Atemwegserkrankungen und Frauengesundheit. Das Unternehmen hat Kooperationsvereinbarungen mit Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd, Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics und Takeda Pharmaceuticals. Das Unternehmen war früher unter dem Namen Evotec AG bekannt und änderte im April 2019 seinen Namen in Evotec SE. Die Evotec SE wurde 1993 gegründet und hat ihren Hauptsitz in Hamburg, Deutschland.